PATH | VRL
Menu

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

This article, published in the New England Journal of Medicine, details a study to evaluate if a high dose (60 µg of hemagglutinin per strain) of trivalent, inactivated influenza vaccine (IIV3) improves protection against laboratory-confirmed influenza illness as compared to the standard dose (15 µg of hemagglutinin per strain). The study found that, among persons 65 years of age or older, the high-dose IIV3 induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did the standard-dose IIV3.

Author: DiazGranados CA, Dunning AJ, Kimmel M, et al.

Published: 2014

» Visit web page (English)

(Located at www.nejm.org)

Citation: DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Older Adults. New England Journal of Medicine. 2014;371(7):635-645.

Resource types: Peer-reviewed journal

Diseases/vaccines: Influenza

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: North America and Europe